Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes
| Autor: | Sean Pinney, Valentin Fuster, Jeffrey W. Olin, Eric Neibart, Jeffrey I. Mechanick, Jonathan L. Halperin, Gennaro Giustino, Robert S. Rosenson |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
BMI
body mass index TRIF Toll/interleukin-1 receptor domain–containing adaptor-inducing interferon-β Disease 030204 cardiovascular system & hematology medicine.disease_cause NIH National Institutes of Health 0302 clinical medicine cardiovascular disease Risk Factors Antithrombotic Medicine 030212 general & internal medicine Prospective cohort study COVID-19 coronavirus disease 2019 Coronavirus TNF tumor necrosis factor CS cytokine storm Thrombosis Host-Pathogen Interactions medicine.symptom Coronavirus Infections Cardiology and Cardiovascular Medicine medicine.medical_specialty Myocarditis Pneumonia Viral Inflammation Lung injury JACC Focus Seminar: Coronavirus Disease 2019 in 2020 SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 Betacoronavirus 03 medical and health sciences Animals Humans SARS severe acute respiratory syndrome TLR toll-like receptor Intensive care medicine Pandemics thrombosis ARDS acute respiratory distress syndrome JACC Focus Seminar SARS-CoV-2 business.industry MERS Middle East respiratory syndrome COVID-19 HCQ hydroxychloroquine medicine.disease IL interleukin COVID-19 Drug Treatment inflammation RNA ribonucleic acid business |
| Zdroj: | Journal of the American College of Cardiology |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/j.jacc.2020.08.058 |
| Popis: | The emergence of a new coronavirus disease (coronavirus disease 2019 [COVID-19]) has raised global concerns regarding the health and safety of a vulnerable population. Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incites a profound inflammatory response leading to tissue injury and organ failure. COVID-19 is characterized by the bidirectional relationship between inflammation and thrombosis. The clinical syndrome is propelled by inflammation producing acute lung injury, large-vessel thrombosis, and in situ microthrombi that may contribute to organ failure. Myocardial injury is common, but true myocarditis is rare. Elderly patients, those with established cardiovascular disease, and mechanically ventilated patients face the highest mortality risk. Therapies for COVID-19 are evolving. The antiviral drug remdesivir, dexamethasone, transfusion of convalescent plasma, and use of antithrombotic therapy are promising. Most require additional prospective studies. Although most patients recover, those who survive severe illness may experience persistent physical and psychological disabilities. Central Illustration Highlights • Severe acute respiratory syndrome coronavirus 2 infection (COVID-19) is a global pandemic affecting millions of people worldwide. • Clinical sequelae result largely from an intense inflammatory response triggering large-vessel and microvascular thrombosis. • No therapy has been universally effective for COVID-19, but systemic anticoagulation, remdesivir, and corticosteroids hold promise. • Long-term sequelae of COVID-19 are variable and incompletely defined, but physical and psychological disabilities can persist. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|